A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Genmab
Revolution Medicines, Inc.
Neonc Technologies, Inc.
AstraZeneca
Eli Lilly and Company
Cantargia AB
Nektar Therapeutics
Incyte Corporation